Page 7 - Aruvant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article NEW YORK, Feb. 3, 2021 /PRNewswire/ -- Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to ARU-1801, a one-time investigational gene therapy for sickle cell disease (SCD).  "PRIME designation from EMA highlights the importance of ARU-1801, administered with only reduced intensity conditioning, for the treatment of individuals with severe sickle cell disease," said Will Chou, M.D., Aruvant chief executiv...

01/18/2021 | Press release | Distributed by Public on 01/18/2021 12:19 Aruvant chooses Lonza to Manufacture ARU-1801, a Potentially curative Treatment for Sickle Cell Disease, for Pivotal Trial Lonza to perform process development activities to establish a robust manufacturing process for ARU-1801, a potentially curative treatment for sickle cell disease Lonza to provide cGMP material supply of ARU-1801 for its use in a pivotal clinical study in the United States Quote from Palani Palaniappan, Chief Technology Officer, Aruvant Sciences: 'We are partnering with Lonza, one of the world's leadin...

Share this article Share this article NEW YORK, Jan. 18, 2021 /PRNewswire/ -- Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant's one-time investigational gene therapy for sickle cell disease (SCD). Aruvant has chosen Lonza to help develop and manufacture ARU-1801 for its upcoming pivotal trial. "We are partnering with Lonza, one of the world's leading cell and gene therapy manufacturing organizations, to help us manufacture our gene therapy ARU-1801, a potential cure for sickl...